Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in chronic kidney disease (CKD) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Northwestern University. Primary endpoints: Left ventricular longitudinal strain at 6 months, Peak oxygen consumption at 6 months and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05719714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719714.